Annual Report and Accounts

RNS Number:4667L
Biofusion PLC
10 January 2008


For immediate release                                            10 January 2008



                                 BIOFUSION PLC

                         ("Biofusion" or "the Company")


             ANNUAL REPORT AND ACCOUNTS FOR YEAR ENDED 31 JULY 2007

Biofusion plc (AIM: BFN), the university IP commercialisation company that turns
world class research into business, announces that on 31 October 2007 the
Company published its report and accounts for the year ended 31 July 2007 and
sent copies to shareholders.

Electronic copies of the report and accounts are available to download on the
investor relations section of the Biofusion website: www.biofusion.com.

Hard copies are available by writing to the Company Secretary at the Company's

registered office: Biofusion plc, The Innovation Centre, 217 Portobello,
Sheffield, S1 4DP.


For further information about Biofusion please contact:

Biofusion                                                     [phone]
David Baynes / Stuart Gall

Buchanan Communications                                       [phone]
Mary-Jane Johnson / Lisa Baderoon / Catherine
Breen

Nomura Code                                                   [phone]
Phil Walker / Clare Terlouw


About Biofusion


Biofusion was established in 2002 to commercialise university-generated IP.
Biofusion has signed long term agreements with two of the UK's top ten research
intensive universities (University of Sheffield and Cardiff University) giving a
combined R&D spend attributable to Biofusion of approximately £114 million a
year. The Company has a portfolio of 23 spin-out companies.


Biofusion's first agreement was a ten-year exclusive arrangement with the
University of Sheffield for the commercialisation of IP owned by the University
in the area of medical life sciences. Biofusion has shareholdings in a portfolio
of Sheffield University spin-out companies including Asterion, Axordia,
Biohydrogen, Diurnal and Phase Focus. The University of Sheffield was ranked 5th
in the UK for the quality of its life sciences research and will be spending an
estimated £0.5bn of research funding over the lifetime over the life of the
Sheffield Agreement.


In January 2007, Biofusion completed a long-term exclusive agreement with
Cardiff University, to commercialise 100% of all Cardiff University's
research-generated IP. Biofusion has shareholdings in a portfolio of Cardiff
University spin-out companies including Abcellute, Q-Chip and Cardiff Protides.
Cardiff University was ranked 7th in the UK in the most recent research rankings
and will be spending over £1.0bn of research funding over the lifetime over the
life of the Cardiff Agreement.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
ACSEAAFNEFFPEAE